EPB-001

EPB-001 is a preclinical **monoclonal antibody** immuno-oncology candidate developed by Elpis Biopharmaceuticals for solid tumors. Available public descriptions identify it as a **human anti-Sialic acid-binding immunoglobulin-like lectin 15 antibody** designed to reverse tumor-associated immune suppression and inhibit tumor growth by blocking Siglec-15 mediated suppressive signaling, including disruption of interactions between tumor-associated macrophages and T cells. The program appears to be positioned as a potential therapy for tumors that are non-responsive or resistant to immune checkpoint inhibitor treatment, but detailed clinical, formulation, and regulatory information has not been publicly established.